Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.Chantale Bernatchez, Adi Diab, Sandra Aung et al.|Journal of Clinical Oncology|2017Cited by 23
A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.Adi Diab, Mario Sznol, Nizar M. Tannir et al.|Journal of Clinical Oncology|2017Cited by 14
PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignanciesAdi Diab, Mario Sznol, Michael E. Hurwitz et al.|Annals of Oncology|2017Cited by 5
P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor MalignanciesV. Papadimitrakopoulou, Adi Diab, Nizar M. Tannir et al.|Journal of Thoracic Oncology|2017Cited by 5
Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma.Michael E. Hurwitz, Nizar M. Tannir, Chantale Bernatchez et al.|Journal of Clinical Oncology|2017Cited by 3